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Defensins are cationic antimicrobial peptides with a broad range of activities against bacteria
and fungi. In the present study, the entire coding sequence of codon-optimized Bovine Neu-
trophil b-Defensin 2 (BNBD2) was designed and placed upstream of Trx coding sequence into
the pET-48b (+) vector. Furthermore, the codon-optimized pelB signal sequences were also
added to the upstream of BNBD2 for periplasmic localization. The periplasmic sorting of
recombinant b-Defensin 2 was evaluated by osmotic shock and SDS–PAGE on the released
proteins. Moreover, the expression of BNBD2-Trx fusion protein was confirmed by the Western
blotting technique. Next, the purification of recombinant protein was achieved by Ni++ affinity
chromatography. BNBD2 was also separated from Trx by chemical cleavage with formic acid.
Finally, both of the antibacterial and antifungal activities of the purified protein were examined.
Overall, the results indicated successful periplasmic production of BNBD2 protein, which
showed antifungal activity against some of Aspergillus species as well as the antibacterial activ-
ity, expressed as successfully suppressed growth of Escherichia coli and Staphylococcus aureus.
 2015 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Antimicrobial peptides, (AMPs), display antimicrobial activity
against gram-negative and -positive bacteria, yeasts, and fungi[1,2]. One of the largest families of AMPs is the defensins
which are found in vertebrates, invertebrates, and plants.
Defensins are cationic peptides with 18–45 amino acid resi-
dues. They have a molecular weight of 2–6 kDa with a frame-
work of 6 Cysteine residues (3 disulfide bonds) [3]. Based on
the relative positions of disulfide bonds, defensins are classified
as a, b or h-defensins [4]. They exhibit various antimicrobial
functions. b-Defensins are able to interact with the charge-
negative cellular membranes of bacteria with high affinity.
Due to the changes in the membrane structure and electric
potential, these peptides can be inserted into the phospholipid
layers of the membranes. Hence, they cause membrane depo-
larization and cell lysis. Antimicrobial effects of b-defensins
816 S. Aghaei et al.depend on the hydrophobicity and distribution of positive
charge amino acids [5]. In domestic cattle, 13 types of
b-defensins with conserved sequences were found in blood neu-
trophil granulocytes [6]. Bovine neutrophil b-defensins
(BNBD1–13) are arginine-rich peptides and include 38–42
amino acids with antibacterial activity [7,8]. Therefore, studies
on BNBDs could develop a new type of antibiotics in the treat-
ment of mastitis in dairy cows. The N-terminal post-
translational modification has been detected in some of
BNBDs; however, the main modification of BNBD2 is the for-
mation of disulfide linkages [6]. To the best of our knowledge,
no study has been done on the production of recombinant
BNBD2 so far. Therefore, BNBD2 can also be a good candi-
date for the production of recombinant antimicrobial peptides
in Escherichia coli.
Cytoplasmic production of recombinant proteins in E. coli
is accompanied by cellular disruption and contamination of
the target proteins with other cytoplasmic components [9].
However, targeting recombinant protein in the bacterial
periplasmic space has the advantage of having less onerous
purification and proteolysis, authentic N-terminus and proper
folding, and suitable biological activity [10,11]. In addition,
the periplasm has a more oxidizing environment than the cyto-
plasm, and favors the formation of the disulfide bonds, which is
important for the activity of respective proteins [12]. Typically,
a signal peptide such as pelB, derived from pectate lyase B of
Erwinia carotovora, is introduced at the N-terminus of recom-
binant proteins to help drive them into the periplasmic space
[13,14]. Moreover, codon optimization of recombinant proteins
or removal of rare codons can increase the efficiency of protein
production in E. coli [15,16]. In this study, the production of a
codon-optimized pelB-BNBD2 with an appropriate direction
into the periplasmic space was found. Notably, this protein
exhibited antibacterial as well as antifungal activities.Material and methods
Construction of the recombinant vector
E. coli, BL21 (DE3) F-ompT hsdsB (rBm) gal dcm, and
pET48b (+) were used as the host and vector, respectively.
Coding sequences (CDS) of the bovine BNBD2 gene (Acces-
sion number, P46160), were obtained via University of Califor-
nia Santa Cruz (UCSC) data bank. Specific sequences,
encoding PelB signal peptide and cleavage site of formic acidFig. 1 Schematic representation for a part of the expression vector pE
pelB-BNBD2 was inserted upstream of Thioredoxin (Trx) encoding se
protein with Trx. As depicted, (Asp-Pro) was designed to facilitate che
protein.(Asp-Pro), were placed at the 50 and 30-terminal ends of
BNBD2 CDS, respectively (Fig. 1). Two web servers, optimizer
(http://www.genoms.uvr.es), and E. coli rare codon analyzer 2
(http://www.faculty.ucr.edu), were performed on BNBD2
CDS. Meanwhile, Codon Adaptation Index (CAI) was used
to evaluate the designed sequences to the Gene script web site
(http://www.gene script.com) (Table 1). The optimized
sequences (250 bp) of pelB-BNBD2 were ordered from the
NedayeFan Company (Tehran, Iran). Synthesized DNA frag-
ments which had been inserted into the pGH vector were
digested with XbaI/NdeI. Subsequently, XbaI-pelB-BNBD2-
NdeI was inserted into the same place in pET48b (+). The
ligation was achieved using T4 ligase enzyme (TaKaRa,
Japan). And finally, the DNA manipulations were carried
out according to the standard protocols [17].
Protein expression
A single colony of recombinant bacteria transformed with
pET48b (+)-BNBD2 was cultured overnight in 5 mL of LB
broth medium which contained 30 lg Kanamycin/mL at 37 
C. The overnight culture was transferred to 50 mL of LB broth
medium. Upon reaching the optical density (OD600) of 0.4–0.6,
the protein synthesis was induced with 1 mM of isopropyl
b-D-1-thiogalactopyranoside (IPTG). The optical density was
measured by the spectrophotometer (Shimadzu, Japan). After-
ward, the temperature of the incubator was set to 30 C. After
another 2–6 h incubation period, the cell pellets were harvested
and re-suspended in TES buffer (Tris 20 mM-EDTA 1 mM,
pH: 8, 20% sucrose). The cells were incubated on ice for
30 min, centrifuged and resuspended in 50 mM of ice-cold
MgSO4, and incubated again on ice for another 30 min. The
periplasmic proteins were collected via centrifugation at
12,000g (4 C) [18]. Further, the supernatants were concen-
trated by Trichloroacetic acid (TCA). Later, equal amounts
of periplasmic protein and the pellet as cytoplasmic protein
were subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE). In addition, the total protein
was obtained by the sonication method with TE buffer
(10 mM Tris, 1 mM EDTA, pH: 7.8) for 30 s and at 50/60Hz.
Western Blotting Analysis
A solubilized protein fraction of each sample was subjected to
SDS–PAGE and transferred to a polyvinylidene difluorideT48b (+) - BNBD2. A codon optimized DNA fragment encoding
quences in pET48b (+) vector. BNBD2 was expressed as a fusion
mical cleavage for release of recombinant BNBD2 from the fusion
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Periplasmic production of bovine neutrophil b-Defensin 2 in E. coli 817(PVDF; Bio-Rad, USA) membrane which had been activated
by soaking it in methanol for 15 s. After blocking the
membrane with TBST-5% (w/v) skim milk for 2 h at room
temperature, the membrane was incubated with a dilution of
mouse anti-(6His) peroxidase antibody (1:2000, Sigma,
USA). The HRP-conjugated IgG bound to each protein band
and was visualized by adding the Tetramethylbenzidine (TMB)
substrate [17].
Purification of Recombinant Protein
The purification procedure was carried out using Ni++ affin-
ity chromatography (His-Bind Quick 300 Cartridges, 70155–3,
Novagen) as described by Swartz [19]. The column was washed
with Wash Buffer (100 mM Tris base, 500 mM NaCl, and
10 mM imidazole, pH: 8) and double sterile H2O, respectively,
and then was charged with 100 mM NiSO4. A 10 mL volume
of periplasmic protein sample (obtained from 350 mL of
recombinant bacterial cultures) was passed through a column,
and the column was washed with the binding buffer (100 mM
Tris base, 500 mM NaCl, and 20 mM imidazole, pH:8) to
remove non-specific bound proteins. Finally, the recombinant
fusion protein was eluted by adding Elution buffer (100 mM
Tris base, 500 mM NaCl, and 500 mM imidazole, pH: 8).
The eluted fractions were collected, and the protein concentra-
tions were determined by the Bradford assay [20]. The purified
protein was concentrated by a 10 kDa cutoff dialysis mem-
brane for removing small peptides. The Fusion proteins were
then digested by treating them with formic acid at final concen-
tration of 50% (v/v) for 24 h in 45 C according to the method
described by Li et al., with some modifications [21]. The
digested products were freeze-dried for 24 h to remove the for-
mic acid. Lastly, Tricine–SDS–PAGE 16% was employed to
detect the purified BNBD2. The mature BNBD2 was again
purified with a Centricon tube (Sartorius Stedim biotech
GmbH) at 4000 g centrifugation and 4 C for 40 min.
Antifungal and antibacterial activities assays
The antifungal effects of the purified BNBD2 protein were
tested against Aspergillus flavus (PTCC 5004) and Aspergillus
parasiticus (PTCC 5018). These strains were purchased as
freeze-dried stock (Persian Type Culture Collection, Tehran,
Iran). The regeneration of these stocks was performed by add-
ing a sterile solution of Tryptic Soy Broth (TSB) (Merck &
Co., Inc., USA). This suspension was spread on solid Sabour-
aud Dextrose Agar (SDA) media and was incubated at 37 C
for mycelium growth of fungi. The 10E4 spores of fungi were
collected aseptically from 10 day-old cultures after neobar
lam calculation. The spore suspensions were later plated on
Mueller-Hinton (M-H) agar, supplemented with 2% glucose
and methylene blue [22]. The fungi were allowed to grow for
two days at 37 C in the central zone of each plate. Standard
paper disks containing different concentrations of purified
BNBD2 (0.05, 0.1 and 0.2 mg/mL) were placed on these
M-H plates. The fusion type of BNBD2-Trx was used as the
negative control, while a kresoxim-methyl antifungal com-
pound was used in two concentrations of 50 and 100 ppm as
the positive control. The plates were incubated at 37 C for
48 h. The antibacterial effects of BNBD2 were assessed by sup-
pressing the growth of Staphylococcus aureus (ATCC25923)
818 S. Aghaei et al.and E. coli (ATCC35218) as typical gram positive and negative
bacteria via a gel diffusion method. The bacterial cells were
grown for lawn seeding in TSB media. Then, the bacterial
inoculates were adjusted to 0.5 McFarland standards and were
completely spread on solid M-H agar plates by surface culture
method using sterile swabs. The wells were created on the
surface of the agar plate in the presence of 0.05, 0.1, and
0.2 mg/mL of BNBD2 and under sterile conditions. Similar
to the previous experiments, BNBD2-Trx was used as negative
control. The plates were then incubated at 37 C overnight.
All of the antifungal and antibacterial activity assays and
the Western blotting analysis were carried out in triplicate.
Results
Codon optimization and cloning
In order to produce bovine BNBD2 in E. coli appropriately,
the codon optimization was performed. The gene script web
server was implemented so as to calculate Codon Adaptation
Index (CAI) of the native bovine BNBD2 CDS. The data indi-
cated that the CAI was 0.61. Thus, the codon optimization was
performed and CAI was measured again to be 0.83, which was
an appropriate index of expression. After obtaining BNBD2
CDS, it was subcloned in pET48b (+), resulting in the produc-
tion of pET48b (+)-BNBD2 (as described in detail in the
Materials and methods section). Proper construction of
pET48b (+)-BNBD2 was confirmed by digestion of the recom-
binant vector with XbaI/NdeI restriction enzymes, yielding two
fragments (250 bp and 5560 bp) (Fig. 2). DNA sequencing was
performed to ensure that no mutations were present in the
sequence of BNBD2 CDS (Data not shown).
Expression and puriﬁcation of recombinant protein and Western
blotting technique
The recombinant vector was transformed into the E. coli cells
to produce the recombinant protein. Afterward, the proteinFig. 2 Agarose gel electrophoresis of double digestion of
plasmid pET48b (+)-BNBD2 using XbaI/NdeI restriction
enzymes. The arrows show desired 250 bp and 5560 bp band
respective to the BNBD2 CDS and the backbone of plasmid.
Marker (DL 5000 DNA Marker, China).production was carried out (as described in the Materials
and methods section). SDS–PAGE gel on proteins released
by osmotic shock indicated a band with an approximate size
of 24 kDa, which was related to the production of BNBD2
fused with Trx-6His. A similar band was also detected in
the bacterial lysate cells (Fig. 3A). Furthermore, the purifica-
tion of recombinant BNBD2-Trx-6His was performed, and
the purified fusion protein was again subjected to the SDS–
PAGE, (Fig. 3B). To ensure the fact that the detected band
was the respective band of BNBD2-Trx-6His, the Western
blotting was carried out by implementing an antibody against
6His tags (Fig. 3C). The concentration of proteins was esti-
mated to be about 4.2 mg/mL. The yield of purified recombi-
nant protein was approximately 12 mg/L of culture media.
Finally, formic acid was used to separate BNBD2 from the
carrier protein (Trx-6His) (Fig. 3D).
Antifungal and antibacterial assays
The antifungal effects of BNBD2 peptide were examined by
the potency of recombinant peptides to inhibit the growth of
two different fungi species. The data indicated a clear inhibi-
tion zone of recombinant peptides when subjected to the plate
of fungi (Fig. 4).
Additionally, the antibacterial activity of BNBD2 was
tested by subjecting the recombinant peptide to the growth cul-
ture of E. coli and S. aureus (as described in the Materials and
methods section). Recombinant purified BNBD2 inhibited the
growth of bacteria compared to the BNBD2-Trx-6His
(Fig. 5). These results showed that BNBD2 was functional
and had a strong potential against fungi and bacterial growth
compared to the negative control.
Discussion
Most defensins have antibacterial and antifungal activities [7].
As a result of the high activity of defensins in vitro, it appears
that the production of defensin would hold promise in applica-
tions for antibacterial and antifungal treatments in the future.
E. coli cells are recognized as suitable hosts for recombinant
protein production due to their rapid growth, simple genetic
background, feasibility for high scale production, and cost-
effectiveness [23].
One of the most important issues which should be consid-
ered is the codon optimization of proteins in heterologous host
cells. Codon optimization could improve the expression of
eukaryotic proteins in E. coli [15]. Hence, the expression of
recombinant human B defensin-2 (hBD2) was reported to
increase 9 fold after the codon optimization [24]. Tiwari
et al. showed that codon optimization and removal of rare
codons could increase periplasmic expression of proteins more
than 100 fold [25]. In the present study, BNBD2 is an arginine
rich peptide with 8 arginine residues. Therefore, rare codons of
arginine (CGC) were subjected for optimization. In the previ-
ous works on BNBD2, the native sequences of the pelB-
BNBD2 gene were cloned into pET48b (+) in an approach
similar to that of this study. However, the amount of recombi-
nant protein was not significant, and the expression was not
satisfactory (unpublished data). Hence, in this study, the
codon optimization was done for the appropriate production
of BNBD2. The pET48b (+) vector containing Trx-tag (as a
Fig. 3 Analysis of expression, purification, and cleavage of BNBD2-Trx-6His recombinant protein. (A) SDS–PAGE analysis of
protein expression of E. coli BL21 (DE3) transformed with pET48b (+)-BNBD2-Trx-6His, 2 h after induction with 1 mM IPTG. Lane
1, the periplasmic proteins after osmotic shock. Lane M, Marker SMO431. Lane 2, the pellet left as cytoplasmic protein. Lane 3, the total
protein pattern. The desired bands are marked with arrows. (B) BNBD2-Trx-6His recombinant protein purified by Ni++ affinity
chromatography. (C) Analysis of Western blotting of BNBD2-Trx-6His recombinant protein that is carried out by implementing an
antibody against 6His tag. (D) Peptide release followed by Tris-Tricine SDS–PAGE (16%). M, Protein marker. Lane 1, the recombinant
protein BNBD2-Trx-6His before cleavage. Lane 2, the recombinant protein, BNBD2-Trx-6His after cleavage with formic acid.
Approximately a 3–8 kDa band as BNBD2 peptide after cleavage is shown.
Fig. 4 Analysis of the antifungal effects of BNBD2 by the disk diffusion method on (a) Aspergillus flavus (PTCC 5004) and (b)
Aspergillus parasiticus (PTCC5018). N: Negative control (recombinant protein BNBD2-Trx), P (1): Positive control: (Kresoxim-methyl
50 ppm), P (2): Positive control (Kresoxim-methyl 100 ppm). A, B and C: 0.05 mg/mL, 0.1 mg/mL and 0.2 mg/mL recombinant purified
BNBD2. The results show inhibition zones of purified BNBD2 peptides.
Fig. 5 Antimicrobial activities of BNBD2 assayed by the agar gel diffusion method. Inoculates of E. coli (ATCC 35218) (a) and S.
aureus (ATCC 25923) (b) were spread on solid agar M-H medium plate. N: Negative control is fusion protein BNBD2-Trx. A, B and C:
0.05 mg/mL, 0.1 mg/mL and 0.2 mg/mL recombinant purified BNBD2 protein.
Periplasmic production of bovine neutrophil b-Defensin 2 in E. coli 819
820 S. Aghaei et al.carrier protein) was used as an expression vector. Due to the
small size of BNBD2 (3–8 kDa), Trx-6His facilitated not
only the identification of recombinant BNBD2 on SDS–PAGE
but also the solubilization of BNBD2. It also inhibited inclu-
sion body (Ib) formation of the desired recombinant protein.
However, the presence of the carrier protein significantly sup-
pressed the antibacterial and antifungal activities of recombi-
nant BNBD2 in E. coli. This showed that the presence of
this carrier protein in E. coli cells was necessary in preventing
the toxic effects of BNBD2 on bacterial host cells. Formic acid
was used to release BNBD2 from the carrier protein. One or
two aspartate residues from the formic acid cleavage site
may remain at the C-terminus of the recombinant BNBD2.
Li et al. stated that although the Asp-x bond is most readily
cleaved by formic acid, the x-Asp may also be cleaved. There-
fore, the resulting peptides may keep at least one aspartyl resi-
due [26]. Due to the negative charge of Asp, adding one or two
Asp at C terminal of BNBD2 may have a negative effect on
protein activity; nevertheless, it has the lowest unfavorable
effect in comparison with other reagents such as enterokinase
or thrombin.
The protein pattern obtained from the total, periplasmic,
and cytoplasmic proteins showed that despite the fact that
the amount of recombinant protein remains in the cytoplasm,
a major part of the expressed recombinant BNBD2 was direc-
ted to periplasmic space. This issue can be accounted for by the
solubility of the recombinant protein which caused efficient
secretion of BNBD2 to periplasmic space. While the majority
of antimicrobial peptides have cysteine residues and disulfide
bonds, periplasm with a more oxidative space than the cyto-
plasm provides the formation of disulfide bonds, true folding,
and better activity of the protein. Zhao et al., reported that ter-
tiary structure is necessary for antimicrobial activity of defen-
sins and increases resistance to bacterial proteases [27].
BNBD2 contains 3 disulfide bonds which play an important
role in the formation of the 3D structure. Therefore, it is
assumed that periplasmic space is a more favorable environ-
ment for the expression of BNBD2. Moreover, there is less
proteolysis and even less onerous purification in this space
[28]. Despite the previous unsuccessful reports [29] on periplas-
mic expression of thionine (as an antimicrobial peptide), this
study successfully showed the periplasmic expression of an
antimicrobial peptide (BNBD2) for the first time. Based on
the research findings of this study, the pelB signal peptide
was suitable for periplasmic expression of this peptide. The
periplasmic space could be a privileged target for purifying
the target protein.
Wu et al. were able to express BNBD12 protein by pET32a
(+) in E. coli. They concluded that BNBD12 had antimicro-
bial activity in E. coli and S. aureus and can control mastitis
[7]. Added to that, Simon et al., reported potent antifungal
properties of human peptide homolog with drosomycin,
drosomycin-like defensin (DLD) in Aspergillus (A. fumigates,
A. nidulans, A. ustus) and Fusarium species [30]. Kazakos
et al., demonstrated the potent antifungal properties of the
human beta defensins (hBD1, hBD2, and hBD3) against repre-
sentative clinical isolates of filamentous fungi; including Asper-
gillus fumigatus, Aspergillus niger, A. nidulans, and Aspergillus
terreus [31]. To investigate the activity of the protein, the
antimicrobial activities of BNBD2 were analyzed on selected
standard model bacteria, i.e. E. coli as a gram negative bac-
terium, S. aureus as a gram positive bacterium, and two majoraflatoxigenic fungi; named A. flavus and A. parasiticus (which
cause liver cancer in humans) [32]. The findings showed that
BNBD2 inhibited the growth of both gram negative and -
positive bacteria and fungi. This semi-quantitative study con-
tinues to search for protein activity, and more characterization
of BNBD2 needs to be discovered.
Finally, in the future, BNBD2 can be used to control mas-
titis in dairy cows. Despite the existence of antifungal and
antimicrobial properties of recombinant BNBD2, further
extensive research on the conformation of this type of BNBD2
is required to ensure that proper disulfide bonds are produced.
Conclusions
A codon optimized pelB-BNBD2 gene for the periplasmic
expression was constructed by the pET48b (+) vector.
Periplasmic expression and purification were successful.
Antimicrobial quantitative study of recombinant BNBD2 on
E. coli, S. aureus, and two Aspergillus sp. showed growth inhi-
bition. Despite the presence of an activity for recombinant
BNBD2, more efforts should be carried out on characteriza-
tion of recombinant BNBD2 to obtain a realistic view of valu-
able data on the expression and antimicrobial properties. In
particular, this activity should be quantified compared to the
conventional antibiotics. Taken together, such studies on
BNBD2 could develop a new generation of antibiotics that
might be effective for treatment of some dairy diseases, such
as mastitis in near future.
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